Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.83 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | CRHR1 | P34998 | 11/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13717181 | 1.00 | CNR1 (0.83) | CNR1CNR2CRHR1CHRM1CRHR2 | |
| SCHEMBL13602503 | 1.00 | CNR1 (0.83) | CNR1CNR2CRHR1CHRM1CRHR2 | |
| SCHEMBL13717094 | 0.97 | CNR1 (0.79) | CNR1CNR2CRHR1CHRM1CRHR2 | |
| SCHEMBL13602727 | 0.92 | CNR1 (0.84) | CNR1CNR2CRHR1CHRM1CRHR2 | |
| SCHEMBL13717645 | 0.91 | CNR1 (0.70) | CNR1CNR2CRHR1CHRM1 | |
| SCHEMBL13717457 | 0.91 | CNR1 (1.00) | CNR1CNR2CRHR1CRHR2 | |
| SCHEMBL13717052 | 0.91 | CNR1 (1.00) | CNR1CNR2CRHR1CRHR2 | |
| SCHEMBL13717281 | 0.91 | CNR1 (1.00) | CNR1CNR2CRHR1CRHR2 | |
| SCHEMBL3928194 | 0.89 | CNR1 (0.66) | CNR1CNR2CRHR1CRHR2RORC | |
| SCHEMBL13602716 | 0.89 | CNR1 (0.66) | CNR1CNR2CHRM1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579369-B2 | CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579369-B2 | CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7294644-B2 | CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294644-B2 | CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070238754-A1 | Novel CB 1 receptor inverse agonists | MAYWEG ALEXANDER | 2007-10-11 | — | — | US | disclosed |
| US-20070238754-A1 | Novel CB 1 receptor inverse agonists | MAYWEG ALEXANDER | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238754-A1 | Novel CB 1 receptor inverse agonists | CNR1, CNR2, GPR139 | CNR1 1/4885CNR2 2/4885CRHR1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.